94 related articles for article (PubMed ID: 22542654)
21. Non-enzymatic platelet-activating factor formation by acetylated proteins.
Thanou PG; Tsoukatos DC
FEBS Lett; 2004 Aug; 573(1-3):11-4. PubMed ID: 15327967
[TBL] [Abstract][Full Text] [Related]
22. Macrophage inflammatory protein-2 mediates the bowel injury induced by platelet-activating factor.
Han XB; Liu X; Hsueh W; De Plaen IG
Am J Physiol Gastrointest Liver Physiol; 2004 Dec; 287(6):G1220-6. PubMed ID: 15319184
[TBL] [Abstract][Full Text] [Related]
23. [Synthesis of paf-acether by E. coli K12].
Thomas Y; Denizot Y; Dassa E; Boullet C; Benveniste J
C R Acad Sci III; 1986; 303(17):699-702. PubMed ID: 3101984
[TBL] [Abstract][Full Text] [Related]
24. [Binding of 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine (thrombocyte activating factor) by plasma components. Exchange of the thrombocyte activating factor between lipoproteins and thrombocytes].
Kulikov VI; Bergel'son LD
Biokhimiia; 1984 Aug; 49(8):1310-5. PubMed ID: 6093897
[TBL] [Abstract][Full Text] [Related]
25. Effects of PAF-antagonists in mouse ear oedema induced by several inflammatory agents.
Merlos M; Gómez LA; Giral M; Vericat ML; García-Rafanell J; Forn J
Br J Pharmacol; 1991 Dec; 104(4):990-4. PubMed ID: 1810607
[TBL] [Abstract][Full Text] [Related]
26. Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds.
Crawford SE; Huang L; Hsueh W; Takami H; Gonzalez-Crussi F; Backer CL; Mu Y; Liu H; Mavroudis C
J Heart Lung Transplant; 1999 May; 18(5):470-7. PubMed ID: 10363692
[TBL] [Abstract][Full Text] [Related]
27. Dose-dependent agonist and antagonist effects of the platelet-activating factor analogue 1-palmitoyl-2-acetoyl-sn-glycero-3-phosphocholine on B lymphocytes.
Mazer BD; Toledano B; Saririan M; Bastien Y
J Allergy Clin Immunol; 1998 Aug; 102(2):231-7. PubMed ID: 9723666
[TBL] [Abstract][Full Text] [Related]
28. Effect of platelet activating factor on the kinetics of LDL oxidation in vitro.
Deigner HP; Dresel HA
FEBS Lett; 1993 Feb; 317(3):202-6. PubMed ID: 8425606
[TBL] [Abstract][Full Text] [Related]
29. [Interaction between Asp-hemolysin-related synthetic peptides and oxidized LDL/lysophospholipids].
Sato A; Ebina K
Seikagaku; 2013 May; 85(5):353-7. PubMed ID: 23819394
[No Abstract] [Full Text] [Related]
30. Identification and pharmacological characterization of platelet-activating factor and related 1-palmitoyl species in human inflammatory blistering diseases.
Travers JB; Murphy RC; Johnson CA; Pei Y; Morin SM; Clay KL; Barber LA; Hood AF; Morelli JG; Williams DA
Prostaglandins Other Lipid Mediat; 1998 Aug; 56(5-6):305-24. PubMed ID: 9990675
[TBL] [Abstract][Full Text] [Related]
31. Platelet activating factor stimulates rapid mucin secretion in rat nasal airways in vivo.
Hotchkiss JA; Stam MA; Harkema JR
Exp Lung Res; 1993; 19(5):545-57. PubMed ID: 8253058
[TBL] [Abstract][Full Text] [Related]
32. A novel oxidized low-density lipoprotein-binding protein, Asp-hemolysin, recognizes lysophosphatidylcholine.
Kudo Y; Ootani T; Kumagai T; Fukuchi Y; Ebin K; Yokota K
Biol Pharm Bull; 2002 Jun; 25(6):787-90. PubMed ID: 12081148
[TBL] [Abstract][Full Text] [Related]
33. A synthetic peptide (P-21) derived from asp-hemolysin inhibits the induction of macrophage proliferation by oxidized low-density lipoprotein.
Kumagai T; Ogawa N; Tsutsumi H; Ebina K; Yokota K
Biol Pharm Bull; 2005 Aug; 28(8):1381-4. PubMed ID: 16079478
[TBL] [Abstract][Full Text] [Related]
34. Antagonism of Paf-induced oedema formation in rabbit skin: a comparison of different antagonists.
Hellewell PG; Williams TJ
Br J Pharmacol; 1989 May; 97(1):171-80. PubMed ID: 2720306
[TBL] [Abstract][Full Text] [Related]
35. PF-5901 inhibits gastrointestinal platelet-activating factor synthesis in vivo.
Hogaboam CM; Donigi-Gale D; Shoupe TS; Wallace JL
Eur J Pharmacol; 1992 Jun; 216(2):315-8. PubMed ID: 1397016
[TBL] [Abstract][Full Text] [Related]
36. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy.
Kasperska-Zajac A; Brzoza Z; Rogala B
Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):72-6. PubMed ID: 19075994
[TBL] [Abstract][Full Text] [Related]
37. Intravitreally injected platelet activating factor induces retinitis in experimental animals.
Rosenbaum JT; Angell E; Wilson D; Broquet C; Boney RS; Braquet P
Curr Eye Res; 1999 May; 18(5):342-8. PubMed ID: 10372995
[TBL] [Abstract][Full Text] [Related]
38. Anti-inflammatory and analgesic effects displayed by peptides derived from PKI55 protein, an endogenous protein kinase C inhibitor.
Selvatici R; Congestrì F; Marzola G; Guerrini R; Siniscalchi A; Spisani S
Naunyn Schmiedebergs Arch Pharmacol; 2010 Sep; 382(3):193-9. PubMed ID: 20644913
[TBL] [Abstract][Full Text] [Related]
39. Release of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema.
Hwang SB; Lam MH; Li CL; Shen TY
Eur J Pharmacol; 1986 Jan; 120(1):33-41. PubMed ID: 3948914
[TBL] [Abstract][Full Text] [Related]
40. [Biological activity of Asp-hemolysin as a regulation factor to atherogenic effect by oxidized low-density lipoprotein].
Kumagai T
Yakugaku Zasshi; 2006 Oct; 126(10):955-64. PubMed ID: 17016024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
